BK virus in the kidney transplant patient

American Journal of the Medical Sciences

Volumn 345, Issue 6, 2013, Pages 482-488

  Kuppachi, Sarat ^a   Thomas, Beje ^b   Kokko, Kenneth E ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

BK virus; Immunosuppression; Kidney transplant

Indexed keywords

CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CIPROFLOXACIN; CYCLOSPORIN; LEFLUNOMIDE; MANITIMUS; MYCOPHENOLIC ACID; PREDNISONE; QUINOLONE DERIVATIVE; RAPAMYCIN; TACROLIMUS; TERIFLUNOMIDE;

BK VIRUS; BK VIRUS INFECTION; CONFERENCE PAPER; GRAFT FAILURE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; PATHOGENESIS; RETRANSPLANTATION; VIREMIA; VIRUS LOAD;

EID: 84878424667     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31826c64ef     Document Type: Conference Paper

References (74)

1. Gardner SD, Field AM, Coleman DV, et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971;1: 1253-7.
2. Purighalla R, Shapiro R, McCauley J, et al. BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 1995; 26:671-3.
3. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002;347:488-96.
4. Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008;3(suppl 2):S68-75.
5. Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999;67:103-9.
6. Babakir-Mina M, Ciccozzi M, Perno CF, et al. The novel KI, WU, MC polyomaviruses: possible human pathogens? New Microbiol 2011; 34:1-8.
7. Jin L, Gibson PE, Knowles WA, et al. BK virus antigenic variants: sequence analysis within the capsid VP1 epitope. J Med Virol 1993;39: 50-6.
8. Shah KV, Daniel RW, Warszawski RM. High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. J Infect Dis 1973;128:784-7.
9. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-23.
10. Goudsmit J, Wertheim-van Dillen P, van Strien A, et al. The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol 1982;10:91-9.
11. Brown DW, Gardner SD, Gibson PE, et al. BK virus specific IgM responses in cord sera, young children and healthy adults detected by RIA. Arch Virol 1984;82:149-60.
12. Polo C, Perez JL, Mielnichuck A, et al. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004;10:640-4.
13. Pietropaolo V, Di Taranto C, Degener AM, et al. Transplacental transmission of human polyomavirus BK. J Med Virol 1998;56:372-6.
14. Zambrano A, Kalantari M, Simoneau A, et al. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate 2002;53: 263-76.
15. Dolei A, Pietropaolo V, Gomes E, et al. Polyomavirus persistence in lymphocytes: prevalence in lymphocytes from blood donors and healthy personnel of a blood transfusion centre. J Gen Virol 2000;81:1967-73.
16. Vera-Sempere FJ, Rubio L, Felipe-Ponce V, et al. Renal donor implication in the origin of BK infection: analysis of genomic viral subtypes. Transplant Proc 2006;38:2378-81.
17. Andrews CA, Shah KV, Daniel RW, et al. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis 1988;158:176-81.
18. Boldorini R, Veggiani C, Barco D, et al. Kidney and urinary tract polyomavirus infection and distribution: molecular biology investigation of 10 consecutive autopsies. Arch Pathol Lab Med 2005;129: 69-73.
19. Chang D, Wang M, Ou WC, et al. Genotypes of human polyomaviruses in urine samples of pregnant women in Taiwan. J Med Virol 1996; 48:95-101.
20. Coleman DV, Gardner SD, Mulholland C, et al. Human polyomavirus in pregnancy. A model for the study of defence mechanisms to virus reactivation. Clin Exp Immunol 1983;53:289-96.
21. Kahan AV, Coleman DV, Koss LG. Activation of human polyomavirus infection-detection by cytologic technics. Am J Clin Pathol 1980; 74:326-32.
22. Reploeg MD, Storch GA, Clifford DB. BK virus: a clinical review. Clin Infect Dis 2001;33:191-202.
23. Sundsfjord A, Flaegstad T, Flo R, et al. BK and JC viruses in human immunodeficiency virus type 1-infected persons: prevalence, excretion, viremia, and viral regulatory regions. J Infect Dis 1994;169:485-90.
24. Sundsfjord A, Osei A, Rosenqvist H, et al. BK and JC viruses in patients with systemic lupus erythematosus: prevalent and persistent BK viruria, sequence stability of the viral regulatory regions, and nondetectable viremia. J Infect Dis 1999;180:1-9.
25. Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis 2003;3: 611-23.
26. Atencio IA, Shadan FF, Zhou XJ, et al. Adult mouse kidneys become permissive to acute polyomavirus infection and reactivate persistent infections in response to cellular damage and regeneration. J Virol 1993;67:1424-32.
27. Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007;2(suppl 1):S36-46.
28. Drachenberg CB, Papadimitriou JC, Wali R, et al. BK polyoma virus allograft nephropathy: ultrastructural features from viral cell entry to lysis. Am J Transplant 2003;3:1383-92.
29. Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000;15:324-32.
30. Hirsch HH, Drachenberg CB, Steiger J, et al. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 2006;577:160-73.
31. Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005;5:2213-21.
32. Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virusassociated nephropathy in children and adults. Transplantation 2003; 75:105-12.
33. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirusassociated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005;79:1277-86.
34. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005;5:582-94.
35. Nickeleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000;342:1309-15.
36. Singh HK, Andreoni KA, Madden V, et al. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol 2009;20:416-27.
37. Gupta M, Miller F, Nord EP, et al. Delayed renal allograft dysfunction and cystitis associated with human polyomavirus (BK) infection in a renal transplant recipient: a case report and review of literature. Clin Nephrol 2003;60:405-14.
38. Petrogiannis-Haliotis T, Sakoulas G, Kirby J, et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med 2001, 345:1250-5.
39. Hariharan S. BK virus nephritis after renal transplantation. Kidney Int 2006;69:655-62.
40. Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 2010;10:407-15.
41. Kuppachi S, Guasch A, Larsen CP, et al. Impact of immunosuppression reduction in BK viremic patients: 3 year follow-up. Am J Transplant 2008;8:284. Abstract.
42. Leung AY, Chan MT, Yuen KY, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2005;40: 528-37.
43. Randhawa PS. Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis 2005;41:1366-7.
44. Portolani M, Pietrosemoli P, Cermelli C, et al. Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase. Antiviral Res 1988;9:205-18.
45. Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 2010;5:1298-304.
46. Waldman WJ, Knight DA, Blinder L. Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology 1999;42:412-8.
47. Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005;352:1157-8.
48. Guasch A, Roy-Chaudhury P, Woodle ES, et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation 2010;90:891-7.
49. Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007;20:962-9.
50. Leca N, Muczynski KA, Jefferson JA, et al. Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol 2008;3:829-35.
51. Liacini A, Seamone ME, Muruve DA, et al. Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation 2010;90:1450-7.
52. Benavides CA, Pollard VB, Mauiyyedi S, et al. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007;84:83-8.
53. Andrei G, Snoeck R, Vandeputte M, et al. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 1997;41:587-93.
54. Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005;5:1997-2004.
55. Bjorang O, Tveitan H, Midtvedt K, et al. Treatment of polyomavirus infection with cidofovir in a renal-transplant recipient. Nephrol Dial Transplant 2002;17:2023-5.
56. Keller LS, Peh CA, Nolan J, et al. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003;18: 1013-4.
57. Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 2003;3:186-91.
58. Lim WH, Mathew TH, Cooper JE, et al. Use of cidofovir in polyomavirus BK viral nephropathy in two renal allograft recipients. Nephrology (Carlton) 2003;8:318-23.
59. Lea AP, Bryson HM. Cidofovir. Drugs 1996;52:225-30; discussion 231.
60. Brody SR, Humphreys MH, Gambertoglio JG, et al. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Clin Pharmacol Ther 1999;65:21-8.
61. Ortiz A, Justo P, Sanz A, et al. Tubular cell apoptosis and cidofovirinduced acute renal failure. Antivir Ther 2005;10:185-90.
62. Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010;89:1057-70.
63. Beadle JR, Hartline C, Aldern KA, et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46:2381-6.
64. Dropulic LK, Cohen JI. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther 2010;88:610-9.
65. Randhawa PS, Schonder K, Shapiro R, et al. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation 2010;89:1462-5.
66. Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006;81:117-20.
67. Wadei HM, Rule AD, Lewin M, et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirusassociated nephropathy (PVAN). Am J Transplant 2006;6:1025-32.
68. Poduval RD, Meehan SM, Woodle ES, et al. Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation 2002;73:1166-9.
69. Ginevri F, Pastorino N, de Santis R, et al. Retransplantation after kidney graft loss due to polyoma BK virus nephropathy: successful outcome without original allograft nephrectomy. Am J Kidney Dis 2003;42:821-5.
70. Ramos E, Vincenti F, Lu WX, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004; 77:131-3.
71. Womer KL, Meier-Kriesche HU, Patton PR, et al. Preemptive retransplantation for BK virus nephropathy: successful outcome despite active viremia. Am J Transplant 2006;6:209-13.
72. Al-Jedai AH, Honaker MR, Trofe J, et al. Renal allograft loss as the result of polyomavirus interstitial nephritis after simultaneous kidneypancreas transplantation: results with kidney retransplantation. Transplantation 2003;75:490-4.
73. Dharnidharka VR, Cherikh WS, Neff R, et al. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant 2010;10:1312-5.
74. Geetha D, Sozio SM, Ghanta M, et al. Results of repeat renal transplantation after graft loss from BK virus nephropathy. Transplantation 2011;92:781-6.